Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer

BACKGROUND: The clinical benefit of a selective cyclooxygenase-2 inhibitor, celecoxib, combined with anticancer therapy in advanced non-small-cell lung cancer (NSCLC) remains unclear. A meta-analysis was performed to address the efficacy and safety of celecoxib in patients with advanced NSCLC. MATER...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Drug Des Devel Ther
Main Authors: Yi, Lilan, Zhang, Wei, Zhang, Hongman, Shen, Jie, Zou, Jingwen, Luo, Peng, Zhang, Jian
Format: Artigo
Sprog:Inglês
Udgivet: Dove Medical Press 2018
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6086108/
https://ncbi.nlm.nih.gov/pubmed/30122902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S169627
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker